Article Per Year (5 Year)
p-Index From 2021 - 2026
2.036
P-Index
This Author published in this journals
All Journal Indonesia Natural Research Pharmaceutical Journal (INRPJ) SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Berdikari : Jurnal Pengabdian kepada Masyarakat Pharmacy Action Journal Jurnal Ilmu Kesehatan MAKIA
Astiani, Rangki
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Civil Engineering, Building, Construction & Architecture Economics, Econometrics & Finance Education Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Nursing Public Health Social Sciences Other

Published : 14 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 14 Documents
Search

 1   2 
DRUG THERAPY IN PATIENTS WITH GRADE 4 DEXTRA HIP OSTEOARTHRITIS WITH COMORBID HYPERTENSION AND TYPE 2 DIABETES MELLITUS Astiani, Rangki; Piter, Piter; Anggraeni, Ria; Luthfiana, Farisa; Sari, Dini Permata; Ramatillah, Diana Laila; Khan, Khasif
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.8977

Abstract

Osteoarthritis (OA) is a chronic degenerative disease that affects the joints, especially heavy joints such as the knees and hips. OA often causes chronic pain and limited mobility, which is even more complex when accompanied by comorbid hypertension and type 2 diabetes mellitus. These comorbidities increase the risk of pharmacotherapy side effects and drug interactions, requiring a multidisciplinary approach and careful clinical pharmacy monitoring. The purpose of this report is to review the pharmacotherapy management of grade 4 OA Hip Dextra with comorbid HT and DMT2, assessing the safety, effectiveness, and role of clinical pharmacists in therapy optimization. A retrospective case study was conducted by analyzing the patient's medical records, including anamnesis, physical examination, laboratory, pharmacological therapy, and clinical response. The analysis was conducted based on the national guidelines of the Indonesian Ministry of Health, the 2021 National Formulary, PERKENI 2023, and PAPDI 2021. The patient was given combination therapy of NSAIDs, analgesics, prophylactic antibiotics, muscle relaxants, gastric protection, and supplementation for anemia. Therapeutic adjustments were made according to the patient's response and laboratory parameters. Clinical pharmacy monitoring ensures pain control, mobility, hemoglobin, and blood sugar. A multidisciplinary approach based on national guidelines has been shown to improve the safety and effectiveness of OA therapy with multiple comorbidities.
ANALYSIS OF CHEMOTHERAPY COSTS IN BREAST CANCER PATIENTS PARTICIPATING BPJS AT DHARMAIS CANCER HOSPITAL JAKARTA Piter, Piter; Astiani, Rangki; Monica, Kristin; Permatasari, Yuri
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.7773

Abstract

This study aims to find out how much chemotherapy costs for inpatient breast cancer chemotherapy patients participating in BPJS and whether there is a difference in real hospital costs compared to INA-CBGs rates. This research is a descriptive, observational study taken from secondary data, in the form of medical record data, laboratory data, INA-CBGs e-claim data and financial data on patient medical costs in accordance with the inclusion and exclusion criteria totaling 100 patient data. Data analysis uses One Sample T-test to see whether there is a significant difference between real costs and INA-CBGs rates. Based on the results of the One Sample T-test, it shows that there is a significant difference. According to the statistical results, a significance of p<0.005 was obtained in class 3 and there was no significant difference in class 1 or class 2. The average cost that breast cancer patients have to pay for each procedure chemotherapy, severity level I Rp. 7,129,348, severity level II Rp. 9,323,275 and severity level III Rp. 9,037,426.
REVIEW ARTIKEL: WAWASAN FARMAKOGENOMIK DAN BIOINFORMATIKA VARIAN GEN ACE DAN PENGARUHNYA TERHADAP RESPONS INHIBITOR ACE PADA HIPERTENSI Anggraeni, Ria; Astiani, Rangki
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.9109

Abstract

Respons terhadap terapi antihipertensi berbasis angiotensin-converting enzyme inhibitors (ACEIs) bervariasi antar individu, yang sebagian besar dipengaruhi oleh faktor genetik. Gen ACE memiliki sejumlah polimorfisme yang dapat memengaruhi kadar enzim dan efektivitas terapi. Penelitian ini bertujuan mengeksplorasi hubungan antara variasi genetik pada gen ACE dan respons terhadap kaptopril, lisinopril, ramipril, dan enalapril pada pasien hipertensi. Penelitian ini menggunakan pendekatan bioinformatika dan farmakogenomik dengan menganalisis data dari PharmGKB, Ensembl, dan GTEx Portal. Polimorfisme genetik dianalisis untuk mengevaluasi keterkaitannya dengan efektivitas ACEI menggunakan pendekatan statistik deskriptif. Empat polimorfisme nukleotida tunggal (SNP) pada gen ACE ditemukan berasosiasi dengan respons terhadap ACEI. Varian rs4291 dan rs1799752 dikaitkan dengan efikasi kaptopril, di mana genotipe AA menunjukkan penurunan keparahan gagal ginjal. Varian rs1799752 juga terkait dengan lisinopril dan enalapril, dengan genotipe DD memberikan penurunan tekanan darah yang lebih besar. Selain itu, rs4359 dan rs4344 berkorelasi dengan efektivitas ramipril, terutama pada genotipe CC+TT dan AA+GG. Kesimpulan: Variasi genetik pada gen ACE berperan dalam menentukan respons terhadap terapi ACEI. Pendekatan farmakogenetik berpotensi meningkatkan efikasi dan keamanan pengobatan antihipertensi
EVALUASI KEJADIAN INTERAKSI OBAT ANTIHIPERTENSI PADA PASIEN RAWAT JALAN DI PUSKESMAS DAYA UTAMA Ningsih, Okta Via; Astiani, Rangki; Budiyanti, Nur Aini; Samor, Vania Amanda
Jurnal Ilmu Kesehatan MAKIA Vol 16 No 1 (2026): Jurnal Ilmu Kesehatan MAKIA
Publisher : LPPM ISTeK ICsada Bojonegoro

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37413/43mx5626

Abstract

Interaksi obat adalah dua atau lebih obat yang diberikan secara bersamaan dapat memberikan efek masing-masing yang diklasifikasikan menjadi interaksi minor, moderat dan mayor. Hipertensi merupakan masalah kesehatan global yang terus berkembang di Indonesia. Tujuan penelitian ini adalah untuk mengidentifikasi potensi interaksi obat antihipertensi pada pasien hipertensi rawat jalan di Puskesmas Daya Utama periode Januari-Maret 2024. Penelitian ini merupakan penelitian non-eksperimental (observasional) dengan pengumpulan data secara retroprospektif menggunakan metode purposive sampling. Hasil penelitian menunjukan bahwa Obat antihipertensi yang paling banyak digunakan dalam penelitian ini yaitu golongan Calcium Channel Blocker (CCB) yaitu obat amlodipine sebanyak 53 resep (92,98%) yang diberikan kepada pasien hipertensi. Potensi interaksi dengan tingkat keparahan minor terjadi sebanyak 8%, moderate sebanyak 85% dan mayor sebanyak 7% dari total 57 pasien hipertensi di Puskesmas Daya Utama periode Januari – Maret 2024. Pasien hipertensi di Puskesmas
Co-Authors Didit Sumardiyanto Farisa Luthfiana Firman Firman Halim, Guntoro Khan, Khasif Kristina, Eka Latief, Fahamsyah Hamdan Liandhajani, Liandhajani Monica, Kristin Muhammad Lukman Hakim, Muhammad Lukman Ningsih, Okta Via Nur Aini Budiyanti Permatasari, Yuri piter, piter Ramatillah, Diana Laila Ria Anggraeni Rizky, Permana Saidah, Andi Samor, Vania Amanda Sari, Dini Permata Seno, Kukuh Setiadi, Novan Sri Endah Susilowati Sukartiningsih, Yulita Vivian, Maria